The GLP-1 derivative NN2211 restores β-cell sensitivity to glucose in type 2 diabetic patients after a single dose

Diabetes

Volumn 52, Issue 7, 2003, Pages 1786-1791

  Chang, Annette M ^a   Jakobsen, Grethe ^b   Sturis, Jeppe ^b   Smith, Marla J ^a   Bloem, Cathie J ^a   An, Bob ^c   Galecki, Andrzej ^d   Halter, Jeffrey B ^a,e  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b NOVO NORDISK A S   (Denmark)

^c NOVO NORDISK INC   (United States)

^d UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^e UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; PLACEBO; PROTEIN NN2211; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE INFUSION; HUMAN; HYPERGLYCEMIA; INSULIN RELEASE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE;

EID: 0038353630     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.52.7.1786     Document Type: Article

References (21)

1. Qualmann C, Nauck MA, Holst JJ, Orskov C, Creutzfeldt W: Insulinotropic actions of intravenous glucagon-like peptide(GLP-1)/7-36 amide in the fasting state in healthy subjects. Acta Diabetologia 32:13-16, 1995
2. Nauck MA, Woolschlager D, Werner J, Holst JJ, Orskov C, Creutzfeldt W, Wilms B: Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM. Diabetologia 39:1546-1553, 1996
3. Nauck MA, Kleine N, Orskov C, Holst JJ, Wilms B, Creutzfeldt W: Normalization of fasting hyperglycemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin dependent) diabetic patients. Diabetologia 36:741-744, 1993
4. Larsson H, Holst JJ, Ahren B: Glucagon-like peptide 1 reduces hepatic glucose production indirectly through insulin and glucagon in humans. Acta Physiol Scand 160:413-422, 1997
5. Toft-Nielsen MB, Madsbad S, Holst JJ: Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care 22:1137-1143, 1999
6. Abraham EJ, Leech CA, Lin JC, Zulewski H, Habener JF: Insulinotrophic hormone glucagon-like peptide-1 differentiation of human pancreatic islet-derived progenitor cells into insulin-producing cells. Endocrinology 143: 3152-3161, 2002
7. Rachman J, Gribble FM, Barrow BA, Levy JC, Buchanan KD, Turner RC: Normalization of insulin responses by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM. Diabetes 45:1524-1530, 1996
8. Zer M, Madsbad S, Madsen JL, Holst JJ: Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta cell function in type 2 diabetes: aparallel group study. Lancet 359:824-830, 2002
9. Knudsen LB, Agerso H, Bjenning C, Bregenholt S, Carr RD, Godtfredsen C, Holst JJ, Huusfeldt PO, Larsen MO, Larsen PJ, Nielsen PF, Ribel U, Rolin B, Romer J, Sturis J, Wilken M, Kristensen P: GLP-1 derivatives as novel compounds for the treatment of type 2 diabetes: selection of NN2211 for clinical development. Drugs Fut 26:677-685, 2001
10. Elbrond B, Jakobsen G, Larsen S, Agerso H, Jensen LB, Rolan P, Sturis J, Hatorp V, Zdravkovic M: Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects. Diabetes Care 25:1398-1404, 2002
11. Agerso H, Jensen LB, Elbrond B, Rolan P, Zdravkovic M: The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia 45:195-202, 2002
12. Juhl CB, Hollingdal M, Sturis J, Jakobson G, Agerso H, Veldhuis J, Porksen N, Schmitz O: Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes. Diabetes 51:424-429, 2002
13. Van Cauter E, Mestrez F, Sturis J, Polonsky KS: Estimation of insulin secretion rates from c-peptide levels: comparison of individual and standard kinetic parameters for C-peptide clearance. Diabetes 41:368-377, 1992
14. Hovorka R, Soons PA, Young MA: ISEC: a program to calculate insulin secretion. Comput Meth Programs Biomed 50:253-264, 1996
15. Kjems LL, Holst JJ, Volund A, Madsbad S: The influence of GLP-1 on glucose-stimulated insulin secretion: effects on β-cell sensitivity in type 2 and nondiabetic subjects. Diabetes 52:380-386, 2003
16. Orskov C: Glucagon-like peptide-1, a new hormone of the entero-insular axis. Diabetologia 35:701-711, 1992
17. Kreymann B, Ghatei MA, Williams G, Bloom SR: Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet ii:1300-1304, 1987
18. Vilsboll T, Krarup T, Madsbad S, Holst JJ: No reactive hypoglycaemia in type 2 diabetic patients after subcutaneous administration of GLP-1 and intravenous glucose. Diabet Med 18:144-149, 2001
19. O'Meara NM, Shapiro ET, Van Cauter E, Polonsky KS: Effect of glyburide on beta cell responsiveness to glucose in non-insulin-dependent diabetes mellitus. Am J Med 89:11S-16S, 1990
20. Hosker JP, Burnett MA, Davies EG, Harris EA, Turner RC: Sulphonylurea therapy doubles B-cell response to glucose in type 2 diabetic patients. Diabetologia 28:809-814, 1985
21. Byrne MM, Sturis J, Clement K, Vionnet N, Pueyo ME, Stoffel M, Takeda J, Passa P, Cohen D, Bell GI, Velho G, Froguel P, Polonsky KS: Insulin secretory abnormalities in subjects with hyperglycemia due to glucokinase mutations. J Clin Invest 93:1120-1130, 1994